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Background: Luminal, estrogen receptor-positive breast cancers represent more than 70% of cases. Despite initial
good prognoses one third of Luminal cancers eventually recur locally or at distant sites and exhibit hormone resistance.
Here we demonstrate that factors elaborated by malignant stromal cells can induce Luminal tumor cells proliferation
and promote angiogenesis and hormone independence. We recently isolated a malignant mouse mammary gland
stromal cell line named BJ3Z that increases proliferation and angiogenesis in estrogen-free xenografted Luminal MCF-7
breast cancer cells.
Methods: BJ3Z and Normal mouse mammary Fibroblasts (NMFs) were expression profiled using microarray assays.
Messenger RNA levels were confirmed by RT-PCR and by immunohistochemistry (IHC). Breast cancer MCF-7, BT-474,
BT-20 and MDA-MB-231cell lines and stromal BJ3Z and NMFs were grown for in vitro assays: breast cancer cell lines
were treated with stromal cells conditioned media, for three-dimensional (3D) mono and co-cultures in Matrigel,
proliferation was measured by Bromo-deoxyuridine (BrdU) incorporation using IHC. Tubule formation in vitro, a proxy
for angiogenesis, was assessed using 3D cultured Human Umbilical cord Vascular Endothelial Cells (HUVEC).
Results: We show that under estrogen-free conditions, BJ3Z cells but not NMFs increase proliferation of co-cultured
Luminal but not basal-like human breast cancer cells in 2D or as 3D Matrigel colonies. Gene expression profiling, RT-PCR
analysis and IHC of colony-derived BJ3Z cells and NMFs shows that Platelet Derived Growth Factor ligands (PDGF-A
and -B) are elaborated by BJ3Z cells but not NMFs; while PDGF receptors are present on NMFs but not BJ3Z cells. As
a result, in colony co-culture assays, BJ3Z cells but not NMFs increase MCF-7 cell proliferation. This can be mimicked
by direct addition of PDGF-BB, and blocked by the PDGF receptor inhibitor Imatinib Mesylate. Both normal and
malignant stromal cells enhance angiogenesis in an in vitro model. This effect is also due to PDGF and is suppressed
by Imatinib.
Conclusions: We provide evidence that Luminal breast cancer cells can be targeted by the PDGF signaling pathway
leading to estrogen-independent proliferation and angiogenesis. We speculate that stroma-directed therapies, including
anti-PDGFR agents like Imatinib, may be useful in combination with other therapies for treatment of luminal cancers.
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Human breast cancer is a heterogeneous disease. Using
expression profiling Perou et al. [1] described several
molecular subtypes among which are three main cat-
egories: Luminal cancers that express Estrogen (ER)
and/or Progesterone (PR) Receptors but lack Human
Epidermal Growth Factor Receptor-2 (HER2); HER2-
overexpressing cancers; and basal-like cancers that lack
ER, PR and HER2. Luminal cancers are by far the most
common (>70% of cases) and have the best prognosis
among the three major subtypes [2]. Clinically Luminal
cancers are treated with endocrine therapies like fulves-
trant or tamoxifen that target ER or aromatase inhibitors
that suppress estrogen production. Despite the initial
effectiveness of these therapies, approximately one-third
of Luminal cancers acquire hormone resistance, enhan-
cing their aggressiveness and leading to local recurrence
or distant metastases [3]. Several mechanisms have been
proposed for growth resumption associated with loss of
regulation by estrogens [4]. Here we address the role of
the tumor microenvironment.
The microenvironment, including peritumoral stroma
that surrounds malignant epithelial cells, plays a major
role in cancer progression and metastasis [5]. Carcinoma
Associated Fibroblasts (CAFs) are the most abundant
cells in such stroma and secrete a variety of factors that
encourage tumor progression [6]. In xenografted human
Luminal MCF-7 cells, CAFs enhance tumor growth and
metastasis and promote angiogenesis by recruiting endo-
thelial progenitor cells. Other studies suggest that CAFs
play a critical role in hormone resistance. For example,
co-culture of tamoxifen-sensitive cells with CAFs signifi-
cantly decreases their sensitivity to tamoxifen while acti-
vating MAPK and AKT pathways [7]. In MCF-7 cells,
CAFs can also induce tamoxifen and fulvestrant resist-
ance by altering mitochondrial functions [8]. Thus the
effects of peritumoral stromal cells in breast cancers are
complex and effective therapeutic targets for hormone
resistance generated by the proximity of such cells may
delay disease recurrence.
Growth factors are important cancer regulators. Platelet-
Derived Growth Factors (PDGF A, B, C and D) be-
long to a four-member family of factors that activate
two tyrosine kinase receptors PDGFR-α and PDGFR-β
[9-11]. PDGF was identified 40 years ago [12] as a con-
stituent of whole blood serum and it is synthesized by
many different cell types, including fibroblasts [13].
PDGF is a mitogen, but it also has significant angio-
genic effects on endothelial cells. In fact, PDGF and
Vascular Endothelial Growth Factor (VEGF) are structur-
ally and functionally related and are conserved throughout
the animal kingdom [10].
PDGF signaling is altered or overactive in many malig-
nancies [9,14-16]. Therapies targeting the PDGFR pathwayreduce tumor growth in prostate [17], endometrial [18],
pancreatic [19] and lung [20] cancers, as well as in
osteosarcomas [21]. In breast cancers, TGF-β initiates
an autocrine PDGF/PDGFR signaling loop critical for
epithelial-to-mesenchymal transition and metastasis [22].
In vitro, PDGF-BB increases proliferation of breast can-
cer cells that can be inhibited by drugs targeting the
PDGF pathway [23]. PDGF also plays a major role in
initiating the “desmoplastic response” of breast cancers
[24,25]. Lastly, patients with recurrent disease have ele-
vated circulating PDGF levels, suggesting that it may
serve as a recurrence marker [26].
We have developed a model to study the effects of
peritumoral stroma in vitro. We previously isolated and
cultured malignant mouse mammary gland stromal cells
we called BJ3Z cells [27]. They are derived from normal
mouse fibroblasts that were transformed by proximity to
human breast cancer cells grown in vivo as xenografts in
immuno-compromised mice. BJ3Z cells are tumorigenic
when injected into mice and enhance angiogenesis and
proliferation of co-injected human MCF-7 cells [28].
Here we address in vitro mechanisms by which BJ3Z
cells control growth and aggressiveness of human breast
cancer cells using normal mammary gland fibroblasts
(NMFs) as controls. We find that unlike NMFs, BJ3Z
cells enhance proliferation of co-cultured Luminal but
not basal-like breast cancer cells. Gene expression profil-
ing shows that malignant BJ3Z cells overexpress PDGF
ligands. We demonstrate that PDGF increases prolif-
eration of Luminal breast cancer cells in the absence
of estrogens. PDGF also stimulates angiogenesis in an
in vitro model. Both effects can be prevented by Imatinib
Mesylate; a potent PDGF receptor kinase inhibitor. Our
studies suggest that stroma-directed therapies including
anti-PDGFR agents may be useful in combination therap-
ies for Luminal cancers.
Methods
Ethics statement
This study did not involve human subjects or clinical
materials. The human breast cancer cell lines are commer-
cially available. The research was approved by University
of Colorado institutional review committees and granting
agencies.
Cell lines
MCF-7 human breast cancer cells were obtained from
the Michigan Cancer Foundation; BT-474, MDA-MB-231,
BT-20 and Human Umbilical Cord Vascular Endothelial
Cells (HUVEC) were from the ATCC (Manassas VA).
Transformed mouse mammary stromal cells (BJ3Z) were
developed in our laboratory [27,29]; normal mouse mam-
mary fibroblasts (NMF) were a kind gift of L. Wakefield
(NCI) [27,29]. All cell lines were authenticated by Single
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Sequencing Core and were mycoplasma-free. Cells were
routinely passaged in minimum essential medium (MEM;
Invitrogen, Carlsbad CA) containing 5% fetal calf serum
(FCS; HyClone, Logan UT). For estrogen-free conditions
the medium was phenol red-free and the serum was
stripped of endogenous hormones by two incubations
with dextran-coated charcoal (DCC). HUVEC cells were
grown in F-12 K medium (ATCC) supplemented with
0.1 mg/ml heparin, 0.05 mg/ml endothelial cell growth
supplement (ECGS; Cat N. 356006 BD Biosciences,
Bedford, MA) and 10% FCS.
BrdU and phosphohistone H3 assays
5-bromo-2'-deoxyuridine (BrdU or BrdUrd) incorpor-
ation in MCF-7 and BT-474 cells was calculated by dual
staining with human CK18 (rabbit polyclonal AP1021;
Calbiochem, La Jolla CA) and BrdU (mouse monoclonal
#347580; Becton-Dickinson, San Jose CA), followed by
red Alexa-555 goat anti-rabbit and green Alexa-488 goat
anti-mouse antibodies (Invitrogen). Basal MDA-MB-231
and BT-20 were stained for human CD44 (rabbit mono-
clonal 1998–1; Epitomics) or CK5 (rabbit monoclonal
2290–1; Epitomics) instead of CK18. For cells grown in
conditioned media, BrdU quantitation was performed by
immunocytochemistry (ICC) using Image J software. For
3D cultures immunohistochemistry (IHC) was used.
Total cells were quantified by counterstaining with blue
fluorescent 4’-6-diamidino-2-phenylindole (DAPI). Anti-
body against phosphorylated Histone H3 (Rabbit pAb
Millipore # 06–570) was used for IHC as described [30].
Proliferation rates were calculated by the ratio of
BrdU + nuclei (green) to DAPI + nuclei (blue) in CK18+,
CD44+ or CK5+ cells (red) using Image Pro 4.5 software
(Media Cybernetics). Quantification of BrdU incorpor-
ation and phosphorylated Histone H3 assays were per-
formed in a minimum of five different fields from three
independent experiments.
Conditioned media
For conditioned media, stock 5% FCS-containing MEM
was removed from BJ3Z cells or NMFs growing in T-75
flasks at 70-80% confluence, and replaced with phenol
red-free medium containing 5% DCC-stripped FCS for
24 h. Media from these cells were collected, filtered and
added to breast cancer cells.
3D colonies
3D culture was performed as described [30]. Briefly, cells
were trypsinized and resuspended in phenol red-free
MEM containing 5% DCC-stripped serum. Breast cancer
cells (10,000-50,000) and/or BJ3Z or NMF cells (50,000)
were layered on Growth Factor Reduced (GFR)-phenol
red-free Matrigel (hereafter called Matrigel) and cultureswere maintained for ~7 days, adding fresh medium
every 2 or 3 days. To calculate proliferation indices,
7 day-old colonies were incubated 1 hr. with
0.25 mg/ml BrdU in 5% phenol red-free, DCC-stripped
serum.
Expression profiling
Briefly, triplicate independent sets of mouse NMF and
BJ3Z cells were grown in Matrigel as 3D colonies [30].
On day 4, colonies were incubated 5–10 min in dispase
(Cat # 354235; BD Biosciences), cells were pelleted, re-
suspended in RLT buffer (QIAgen, Germany), homoge-
nized (QIAshredder™; Cat # 79654, QIAgen) and RNA
was extracted (RNEasy mini-kit™; Cat # 74104; QIAgen).
Microarray analyses were performed at the University of
Colorado Microarray Core using Affymetrix mouse gene
ST 1.0 chips. Data were analyzed with Partek Genomics
Suite Software 6.6 (Partek Ltd.). Raw data were normal-
ized and analyzed to obtain significant differences by
comparing NMF versus BJ3Z using t-test of unequal
variances. The results were organized by p values (false
discovery rates, FDR) of 0.05 and 0.01. This generated
lists of 5,049 and 234 probesets that were significantly
and differentially up- or down-regulated in NMF vs.
BJ3Z cells respectively (Additional file 1: Table S1).
Semi-quantitative RT-PCR
Briefly, total RNA samples (1–2 μg) were reverse tran-
scribed using SuperScript II RT (Invitrogen), and cDNA
samples were amplified by PCR using specific primers
against FGF-5, IGF2BP3, IGF2BP1, PDGF-A, PDGF-B,
DAPK-1, Caveolin-1, TGF-β1, TGF-β2, PDGFR-α and
PDGFR-β (primer sequences are summarized in Additional
file 1: Table S1); β-actin was used as a loading control. In
all cases a PCR cycle versus intensity curve was obtained
to confirm that amplified PCR products were in the linear
area of the curve.
PDGFR inhibition and recombinant PDGF
The PDGFR inhibitor Imatinib as its mesylate salt (IM;
also Gleevec™, Glivec or STI571), was kindly provided by
Novartis Pharma AG (Switzerland). Cells were incubated
with 10 μM IM in sterile water for 6 h (tubule formation
assay) or 48 h (3D proliferation assay). 3D colonies of
MCF-7 cells were treated 48 h with 30 ng/ml recombin-
ant human PDGF-BB (Cat N. 14-8501-80; eBioscience,
San Diego, CA) [31].
IHC for PDGFs & PDGFRs
IHCs were performed on paraffin sections (4–5 μm) of
NMF and BJ3Z cells cultured in 3D colonies as described
[30]. They used antibodies directed against PDGF-A
(sc-7958; rabbit polyclonal, Santa Cruz), PDGF-B (sc-7878;
rabbit polyclonal, Santa Cruz), PDGFR-α (AF1062; goat
Pinto et al. BMC Cancer 2014, 14:735 Page 4 of 12
http://www.biomedcentral.com/1471-2407/14/735polyclonal, R&D systems) and PDGFR-β (AF1042; goat
polyclonal, R&D systems). Briefly, sections were deparaffi-
nized and antigen retrieval was performed in a pressure
cooker (Bio-care Medical) at 20 psi for 5 min in cit-
rate buffer (10 mM sodium citrate, 0.05% Tween-20,
pH 6.0). Sections were blocked 30 min with 10% normal
goat serum and primary antibodies were applied for 1 hr.
Fluorescent secondary antibodies were: Alexa fluor 555
(red) donkey anti-goat IgG (1:300) and Alexa fluor 488
(green) goat anti- rabbit IgG (1:400; both Invitrogen).
Cell nuclei were counterstained with 4-6-Diamidino-2-
phenylindole (DAPI). Fluorescent images were obtained
using a Nikon Eclipse E600 fluorescent microscope
coupled to a RGB-MSC micro color camera, and Image
Pro Plus software version 4.5 (Media Cybernetics, Silver
Spring, MD).
In vitro tubule formation
HUVEC cells were counted, pelleted and resuspended in
phenol red-free medium containing 5% DCC-stripped
serum; in F-12 K (a positive control containing Endothelial
Cell Growth Supplement, BD Biosciences #356006); or in
48 hr-conditioned media from NMFs or BJ3Z cells
grown in phenol red-free medium and 5% DCC-
stripped serum. HUVEC were seeded in duplicate into
8-well chambers (40,000 cells per well) pre-coated with
Matrigel. Cells were incubated for 24 h, with images
captured every 2 hours. Cells were photographed in a
Nikon Eclipse Ti microscope coupled to a Nikon digital
camera DS-Qi1Mc. Images were analyzed and quanti-
fied in NIS-Elements AR software version 3.2 (Nikon
Corp.). For quantification, the lengths of ten tubular
structures/field were measured in duplicate per condi-
tion at 6 h of incubation. The experiment was repeated
three independent times with similar results.
Results
Malignant BJ3Z stromal cells but not normal mouse
mammary fibroblasts (NMFs) enhance proliferation of
Luminal and HER2-positive breast cancer cells
BJ3Z are pure malignant mouse mammary stromal cells
that arose after fusion of normal mouse stromal cells
with human breast cancer cells xenografted into mam-
mary glands [27]. When originally isolated, the cells con-
tained both human and mouse chromosomes. However,
after long-term culture all contaminating human chro-
mosomes were lost as demonstrated by karyotype, single
tandem repeat, and fluorescent in situ hybridization ana-
lyses [27]. The pure mouse malignant stromal cell line
was called BJ3Z. The cells express the classical markers
of activated fibroblasts when cultured in 3D [28] and
have low proliferation rates. They were therefore used
as a model of malignant stromal cells. In ovariecto-
mized (ovx’d) immuno-compromised mice, BJ3Z cellsare tumorigenic alone. In xenografts, BJ3Z cells en-
hance growth and angiogenesis of co-injected estrogen-
dependent human MCF-7 breast cancer cells [28].
NMFs lack these properties.
Luminal breast cancer cells usually require estrogens
for growth. To explain the non-estrogenic in vivo
growth-promoting and angiogenic effects of BJ3Z
cells on Luminal cells, BJ3Z were compared to NMFs
using in vitro assays. First, we evaluated if a factor
secreted by BJ3Z cells preferentially affects growth of
breast cancer cells. For this media conditioned by growth
of BJ3Z cells or NMFs, or control cell-free medium, were
filtered and re-incubated for 2 days with cultured human
breast cancer cells whose media had been removed. The
tested cells represent the 3 main subtypes: MCF-7,
Luminal A; BT-474, Luminal B/HER2+; MDA-MB-231
and BT-20, basal-like. One hour before the end of the
study cells were pulsed with BrdU then processed for
ICC. Figure 1A shows the 4 breast cancer cell lines
exposed to conditioned media from control, BJ3Z cells
or NMFs; stained for BrdU (green), Luminal CK18 or
basal CK5 (red); and counterstained with DAPI (blue).
(Note that BT-20 cells express CK5, classifying them as
“triple negative” within the basal-like subtype.) Data were
quantified as the BrdU/DAPI ratio (Figure 1A, right). With
regard to the Luminal MCF-7 and BT-474 cells, BJ3Z-
conditioned medium significantly increased proliferation,
while control and NMF-conditioned media had no effect.
However, effects were different on the basal-like cells,
where surprisingly, BJ3Z-conditioned media strongly
suppressed growth.
To confirm that a BJ3Z-secreted factor had differential
effects on Luminal vs. basal-like breast cancer cells, we
designed an assay in which malignant BJ3Z cells or nor-
mal NMFs were co-cultured with the 4 human breast
cancer cells and grown as 3D Matrigel colonies in vitro.
In 3D, cell growth more closely resembles in vivo condi-
tions than growth on plastic [32,33]. Mono-culture of
the breast cancer cells served as controls (Figure 1B).
Colonies were pulsed 1 hr. with BrdU at the end of the
study and harvested for IHC [30]. Luminal cells were
detected with CK18; basal-like cells with CD44 or CK5
(both in red); all cells were stained for BrdU incorp-
oration (green) and counterstained with DAPI (blue).
Proliferation of breast cancer cells was quantified as
the BrdU/DAPI ratio (Figure 1B, right). Note that the
morphology of colonies differs depending on the cell
types in the mixtures, requiring that cell type-specific
markers be used for quantitation. Interestingly, stromal
cell proliferation appears to be negligible under 1 hr. BrdU
incorporation conditions (Figure 1B). Similar quiescence is
observed for stromal cells in 3D monoculture. However
stromal cell proliferation can be detected if longer BrdU
incubation conditions are tested (data not shown).
Figure 1 Malignant stroma regulates proliferation of breast cancer cells in vitro. A. MCF-7, BT-474, MDA-MB-231 and BT-20 breast cancer
cells growing as monocultures in 2D on plastic, were incubated with control media, or media conditioned (CM) by BJ3Z or NMF stromal-like cells.
Proliferation of the breast cancer cells was quantified by immunocytochemistry (ICC) for percent BrdU incorporation (green nuclei) compared to
total cells (DAPI; blue), n = 3. Breast cancer cells were counterstained by ICC for Cytokeratin-18 (CK18, red). Bar: 100 μm. B. The same breast cancer
cell lines were cultured in 3D on Matrigel and grown as colonies in monoculture or co-culture with BJ3Z or NMF cells. Colonies were stained by
immunohistochemistry (IHC). Proliferation was quantified by counting BrdU incorporation (green nuclei) compared to total cells (DAPI, blue). To
visualize the breast cancer cells they were counterstained with markers previously determined to be appropriate for each: CK18 (red) for MCF-7
and BT-474; CD44 (red) for MDA-MB-231; CK5 (red) for BT-20, n = 3. Bar: 100 μm *p < 0,05 by ANOVA followed by Tukey’s post-test.
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onstrates that BJ3Z cells significantly enhance growth of
co-cultured MCF-7 and BT-474 cells, but fail to do so or
even suppress growth of basal-like cells. Effects of NMFare not significant. This confirms in an entirely inde-
pendent manner that factor(s) produced by BJ3Z cells
preferentially stimulate growth of Luminal breast cancer
cells.
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BJ3Z vs. NMF
To identify soluble factors elaborated by BJ3Z cells and
responsible for Luminal cell proliferation, BJ3Z cells and
NMFs were gene profiled after isolation from 3D col-
onies. Figure 2A shows that when grown in Matrigel
under hormone-free conditions both BJ3Z cells and
NMFs form 3D colonies that are similar in size and
morphology. Cells were isolated from three independent
sets of BJ3Z and NMF colonies, RNA was extracted
and profiled using mouse GeneChip 1.0 ST Affymetrix
arrays that probe more than 26,000 mouse transcripts.
Figure 2B shows a hierarchical clustering of the tripli-
cate sets, highlighting genes that are significantly (p < 0.05)
and differentially up- (red) or down- (green) regulated
in one cell type compared to the other. Differentially
expressed genes were analyzed in detail and lists are
available (Additional file 2: Table S2). Microarray re-
sults we confirmed on a select subset of secreted
growth factors and other factors known to be com-
monly up- or downregulated in malignant stromal cells.
These transcripts included: Death Associated Protein
Kinase-1 (DAPK-1), Fibroblast Growth Factor-5 (FGF-5),
Caveolin-1, Insulin-like Growth Factor-2 Binding Protein-1
and −3 (IGF2BP-1, IGF2BP-3), Transforming Growth
Factor beta-1 and −2 (TGFβ-1, TGFβ-2), Platelet De-
rived Growth Factor-A and –B (PDGF-A, PDGF-B) and
the PDGF Receptor-α and β (PDGFR-α, PDGFR-β).
Differential expression of these transcripts in each cell
type was confirmed by RT-PCR using β-actin as a load-
ing control (Figure 2C, lower panel). Interestingly, the
two main ligands of the PDGF pathway, PDGF-A and
PDGF-B, which regulate cell growth and angiogenesis
[13], are upregulated in BJ3Z cells while the two
PDGF receptors, PDGFR-α and PDGFR-β are upregu-
lated in NMFs. To confirm that transcript expression
was reflected in protein levels, expression of the PDGF
pathway members were analyzed by IHC (Figure 2D).
This confirms that NMFs express the receptors but not
the ligands; while BJ3Z cells express the ligands but not
the receptors.
Since expression profiling, RT-PCR and IHC demon-
strated that PDGF ligands are produced by BJ3Z cells
(Figure 2C and D), we evaluated the role of PDGF
on Luminal cell proliferation (Figure 3). First we asked
whether the Luminal-cell stimulatory factor(s) elabo-
rated in BJ3Z-conditioned media involves PDGF by add-
ing Imatinib Mesylate (IM), a potent tyrosine kinase
inhibitor of PDGFRs. As shown in Figure 3A, on plastic,
conditioned medium from BJ3Z cells increases prolifera-
tion of MCF-7 cells. Concomitant incubation of MCF-7
cells with BJ3Z-conditioned medium plus IM completely
prevents the increased proliferation. IM was also able to
block the direct effects of BJ3Z cells in 3D cultures. Forthis, MCF-7 cells were grown in 3D Matrigel cultures
alone, or in co-culture with BJ3Z cells in the absence
or presence of IM. BJ3Z cells increased proliferation
of MCF-7 cells; and this effect was blocked by IM in
a statistically significant manner (Figure 3B). Thus
two different experimental models demonstrate that
the proliferative effects of BJ3Z cells on MCF-7 cells
are mediated by PDGF and can be suppressed by IM,
presumably via PDGFR inhibition. The direct role of
PDGF in promoting breast cancer cell growth was
confirmed by treating MCF-7 cells grown in 3D-cultures
with PDGF-BB; a ligand that binds all PDGFRs. PDGF-
BB caused a significant increase in MCF-7 cell mitosis
as measured by phosphorylation of Histone H3 (pHH3,
Figure 3C). Additional studies probing BrdU incorpor-
ation into PDGF-BB-treated MCF-7 cells yielded similar
results (Figure 3D). Thus, it is clear that PDGF secreted
by malignant BJ3Z stromal cells increase proliferation
of neighboring Luminal MCF-7 breast cancer cells via
a pathway that does not involve estrogens.
Tubule formation in vitro and the PDGF pathway
Besides being a potent mitogen, PDGF also induces
angiogenesis [13]. Previously, we demonstrated that
BJ3Z cells enhance angiogenesis in vivo [28]. Here
we assess a possible mechanism by comparing the
in vitro tubule formation properties of BJ3Z cells vs.
NMFs using Human Umbilical Cord Vascular Endothelial
Cells (HUVEC) [34,35]. For this, HUVEC cells were
seeded into chambers pre-coated with phenol red-free/
growth factor reduced Matrigel and incubated with
non-conditioned control medium, BJ3Z cell or NMF-
conditioned media, or F12K medium. Chambers were
photographed and the lengths of ten tubular structures/
field in three independent experiments were measured
per condition after 6 h of incubation. Compared to con-
trol medium, media conditioned by BJ3Z cells or NMFs
induced a statistically significant increase in formation
of HUVEC tubular structures (Figure 4A top). Quanti-
fication of the data (Figure 4A, bottom) showed that
NMF-conditioned medium significantly increased tu-
bule formation compared to control medium. BJ3Z-
conditioned medium caused a significant further increase
in tubule formation compared to either control or NMF-
conditioned media. Tubule formation levels obtained
with BJ3Z-conditioned medium were similar to ones
induced by F-12 K – a supplement that contains pro-
angiogenic factors. Finally, to test the influence of the
PDGF pathway on tubule formation, BJ3Z cell- and
NMF-conditioned media were co-incubated with HUVEC
cells together with IM. Figure 4B shows that addition
of IM blocked the increased tubule formation pro-
duced by BJ3Z- and NMF-conditioned media. We con-
clude that stromal elements, and in particular malignant
Figure 2 Expression profiling of NMF and BJ3Z. A. Hematoxylin & eosin stained clusters of NMF or BJ3Z cells cultured in Matrigel, bar: 100 μm.
B. Hierarchical clustering of microarray data NMF (blue box) versus BJ3Z (red box), n = 3, using ANOVA p < 0.05. C. Sub-selected genes down
(in green) or up-regulated (red) in BJ3Z cells by microarray were confirmed by semi-quantitative RT-PCR (lower panels), β-actin levels were used as
loading control. D. NMF or BJ3Z cells in Matrigel were stained for members of the PDGF pathway: PDGF-A, PDGF-B, PDGFR-α and PDGFR-β.
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breast cancer cells, but also enhance tubule forma-
tion in vitro, an indicator of angiogenesis, via PDGF
signaling.Discussion
Malignant stroma
Luminal tumors represent the great majority of breast
cancer cases. These malignancies of mammary gland
Figure 3 The PDGF pathway regulates proliferation of Luminal MCF-7 cells in vitro. A. MCF-7 cells in 2D on plastic were incubated with
control or BJ3Z cell-conditioned media (CM) in the absence or presence of Imatinib Mesylate (IM). Percent of cells incorporating BrdU were
compared to total cells (DAPI) to quantify proliferation; n = 3, *p < 0,05 by ANOVA followed by Tukey’s post-test. B. MCF-7 cells in 3D Matrigel
monoculture, or co-cultured with BJ3Z cells, were treated with IM for 48 hr. BrdU incorporation (green nuclei) into MCF-7 cells was used to
quantify proliferation compared to total cells (DAPI; blue nuclei). Cytokeratin-18 (red)-positivity mark the Luminal MCF-7 cells; BJ3Z cells are
CK18-negative; n = 3; bar denotes 100 μm. Quantification of data is on the right with *p < 0,05 by ANOVA followed by Tukey’s post-test.
C. MCF-7 cells in 3D Matrigel colonies were treated with recombinant PDGF-BB, 30 ng/ml for 48 hr. Phosphorylated-Histone H3 expression
was quantified by IHC, n = 3, bar: 100 μm. *p < 0,05 by Student’s t-test. D Proliferation in PDGF-BB treated MCF-7 cells was quantified by
BrdU incorporation, n = 3, *p < 0,05 by Student’s t-test.
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ER, such as tamoxifen or fulvestrant, or therapies that
target E biosynthesis, such as aromatase inhibitors. Des-
pite their initial good prognosis and responses to these
therapies, approximately one-third of Luminal cancers
become resistant to therapies and recur either locally or
at metastatic sites [3]. However, malignant epithelial
cells do not exist in isolation within primary tissues or
in recurrent or metastatic tissues. In all cases, the malig-
nant epithelial cells are surrounded by and embedded in
local tissue parenchyma. In normal tissues the cellular
compartment located beneath the epithelium is the
stroma, whose predominant cells type is the fibroblast.
Stromal fibroblasts play a key role in a wide variety of
normal biological processes. Additionally, multiple stud-
ies have shown that in cancers, carcinoma associated
fibroblasts (CAFs; or “malignant stroma”) modify the be-
havior of the surrounding malignant epithelial cells bynurturing their growth and supporting their progression,
invasion and metastasis [36-38]. CAFs do so by secret-
ing a variety of growth factors, chemokines and prote-
ases [39]. In breast cancers, malignant stroma also
appears to play a role in resistance to therapies and
tumor recurrence [7,8]
Proliferation
We previously demonstrated that a mouse mammary
gland malignant stromal cell line that we derived and
termed BJ3Z, enhances the in vivo proliferation of
Luminal MCF-7 breast cancer cells [28] in the absence
of estrogen supplementation. This is critical because
Luminal tumors are classically thought to be estrogen-
dependent. Our studies suggested that malignant stroma
can replace estrogens as the proliferative agents. In the
present studies we address mechanisms by which malig-
nant stroma might do so. Importantly, as controls for
Figure 4 The PDGF pathway regulates angiogenesis of HUVEC in vitro. A. HUVEC were incubated with control (5 % DCC medium) or
conditioned media (CM) obtained from either NMF or BJ3Z cells, F-12 K supplement was also used as a positive angiogenesis control; bar
500 μm. Tubule length quantification is shown on the lower panel, n = 3, * and # p < 0,05 by ANOVA followed by Tukey’s post-test versus control.
B Imatinib mesylate (IM, black bars) was added to HUVEC; n = 3, *p < 0,05 by Student’s t-test versus control.
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used normal mouse mammary fibroblasts (NMFs).
Our in vitro results show that in the absence of estro-
gens, proliferation of Luminal MCF-7 cells is enhanced
by BJ3Z cells but not by NMFs. Interestingly this
proliferative effect is restricted to Luminal cells, since
proliferation of basal-like MDA-MB-231 and BT-20
cells is unaffected by BJ3Z cells (Figure 1). A study
using human reduction mammary fibroblasts immor-
talized with h-TERT also found increased levels of
proliferation restricted to the Luminal breast cancer
cell subtype [40].
Our results demonstrate that the increased Luminal
breast cancer cell proliferation is dependent on PDGF li-
gands secreted by the malignant stromal cells. Since the
effects of PDGF are observed in vitro, we speculate that
this represents paracrine signaling that targets PDGF
receptors present on the breast cancer cells. Since PDGF
receptors are expressed on breast cancers [41] and
breast cancer cell lines including MCF-7 cells [42] this is
a likely mechanism for the proliferative effect we ob-
serve. The PDGF pathway has been implicated in prolif-
eration and angiogenesis in many malignancies. Indeed,
PDGF and/or PDGF receptors are expressed in a variety
of malignancies including melanoma [43] colorectal [44],
lung [45], colon [46], cervical [47] and breast cancer
[48]; in all cases PDGF signaling plays a key role in
tumor growth and progression.
Breast cancer patients have higher levels of PDGF and
VEGF in both tumors and sera compared to normalcontrols [49]. PDGF-B expression predicts micrometas-
tases in peripheral blood, bone marrow and sentinel
lymph nodes of breast cancer patients [50], and plays a
key role in initiating the desmoplastic response [24,25].
A recent study suggests that the PDGF pathway also
plays a key role in therapeutic resistance. Proliferation of
estrogen-deprived MCF-7 cells can be restored by over-
expressing PDGFR-β. Additionally, ER + breast tumors
of menopausal women undergoing neoadjuvant therapy
with an aromatase inhibitor exhibit increased PDGFR-β
expression [51]. These data suggest that the PDGF pathway
may be upregulated in hormone-resistant Luminal tumors
making it a potential target for reversing resistance.
Angiogenesis
Solid tumors require blood vessels to grow beyond a few
millimeters in diameter. Angiogenesis is the mechanism
by which these new blood vessels are generated and it is
therefore one of the “hallmarks of cancer” [52,53]. CAFs
are the main source of VEGF; a potent morphogen for
endothelial cells and the classical factor implicated in
angiogenesis [54]. VEGF also increases vascular leaking
and is a chemoattractant for circulating endothelial
progenitor cells [55]. Orimo and colleagues [38] showed
that co-injection of human CAFs and Ras-mutant MCF-7
cells generated highly vascularized tumors and proposed
a mechanism involving secretion of Stromal-Derived
Factor-1 (SDF-1) by CAFs into the bloodstream and
mobilization and recruitment of circulating endothe-
lial progenitor cells to form new blood vessels within
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angiogenesis when co-injected with MCF-7 cells and that
BJ3Z cells express SDF-1 in 3D cultures and tumors [28].
We therefore speculated that SDF-1 was the angiogenic
factor. Here we show additionally, that BJ3Z-conditioned
media enhance tubule formation of HUVEC cells in a
PDGF-dependent manner. Thus it appears that at least
two factors secreted by BJ3Z cells, and perhaps more, can
induce angiogenesis; and highlights the complexity of this
process. PDGF-induced angiogenesis has been described.
Overexpression of PDGF-B in keratinocytes [56] and
gliomas [57] increases angiogenesis. In gliomas, PDGF-B
stimulates VEGF, which enhances proliferation of endothe-
lial cells and the recruitment of vascular smooth muscle
cells (pericytes) to form new blood vessels. It is possible
that both paracrine and autocrine loops can explain the
PDGF effects we observe, since Luminal cells also secrete
VEGF [58]. Additionally, during angiogenesis, the PDGF
pathway regulates recruitment of pericytes into newly
formed vessels, and endothelial cell-derived PDGF-B stim-
ulates their proliferation and migration via PDGFRβ
[59,60]. During angiogenesis, pericyte recruitment stabi-
lizes immature endothelial tubes in a process that also
requires PDGF-B [61,62]. Conversely PDGFR blockade
causes pericyte detachment and blood vessel regression
thereby decreasing tumor growth [63-65]. Therefore there
is the possibility that key targets of stromal PDGF are
perivascular smooth muscle cells.
Targeting PDGF in breast cancers
IM is a tyrosine kinase inhibitor originally developed
as an inhibitor of the BCR-ABL kinase which causes
chronic myeloid leukemia (CML). It has been success-
fully used for the treatment of CML, as well as gastro-
intestinal stromal tumors, which are typically driven by
gain-of-function mutations in the KIT tyrosine kinase
receptor [66]. IM also targets PDGF receptors [67] and
recent studies have evaluated its use in breast cancers.
These show that IM inhibits breast cancer cell prolifera-
tion by inhibiting telomerase activity [68]; inhibits phos-
phorylation of PDGFR-β in MDA-MB-231 breast cancer
cells [69]; and increases sensitivity of breast cancer cell
lines to radiotherapy [31] in vitro. In mice, IM sup-
presses orthotopic MDA-MB-231 tumor growth [69]
and decreases osteolytic lesions and metastatic tumor
burden generated by these cells. In combination with
Paclitaxel, IM inhibits growth, PDGFR phosphorylation,
cell proliferation, and tumor microvessel density of
MDA-MB-435 metastases in bone [70]. As a result, IM
has been evaluated for use in metastatic breast cancer
patients. In a phase II trial IM in combination with
Capecitabine in 19 such patients (68% ER + and/or PR+)
was well tolerated, but response rates were not different
than with Capecitabine alone [71]. A second phase II trialevaluated IM in combination with Docetaxel in 37
patients with metastatic disease (49% ER+). This study
reported poor tolerance and low objective response with
the combinations, compared to Docetaxel alone [72]. It is
likely that anti-PDGF receptor therapies, like all targeted
therapies, will require that patients be selected on the
basis of clearly defined criteria, including the presence of
PDGR receptors on their tumor cells. Moreover, our stud-
ies suggest that such drugs may be especially useful as
second-line therapy in Luminal disease with demonstrated
hormone resistance.Conclusions
Malignant stromal cells enhance proliferation of human
Luminal breast cancer cells in the absence of estrogens.
They also stimulate in vitro tubule formation; a marker
of angiogenesis. Both mechanisms could be linked to
endocrine therapy resistance. We speculate that stroma-
directed therapies, including anti-PDGFR agents like
Imatinib, may be useful in combination with other ther-
apies for treatment of Luminal cancers.Additional files
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